ArticleFrontiers in oncology2025
Polyamine metabolism related gene index prediction of prognosis and immunotherapy response in breast cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Opposing Roles for ATP13A2 and ATP13A3 in Breast Cancer Subtype-Specific Polyamine Homeostasis.Biomolecules · 2026Article
- Polyamine metabolism in cancer: drivers of immune evasion, ferroptosis and therapy resistance.Expert reviews in molecular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polyamine metabolism is closely associated with tumorigenesis, progression, and the tumor microenvironment (TME). This study aimed to determine whether polyamine metabolism-related genes (PMRGs) could predict prognosis and immunotherapy efficacy in Breast Cancer (BC). Methods: We conducted a comprehensive multi-omics analysis of PMRG expression profiles in BC. Consensus cluster analysis was used to identify PMRG expression subtypes in the METABRIC cohort. Univariate and multivariate Cox regression analyses were performed to identify independent prognostic genes, which were subsequently used to construct a predictive model for BC, along with a novel nomogram based on PMRGs. The model was validated using an independent cohort (GSE86166). Independent prognostic genes were further verified in BC tissues using quantitative real-time PCR (qRT-PCR), Semi-quantitative Western blot, and immunohistochemistry. Additionally, we analyzed the immune microenvironment and enriched pathways across different subtypes using multiple algorithms. Finally, the "oncoPredict" R package was used to assess potential drug sensitivities in high-risk and low-risk groups. Results: Seventeen polyamine metabolism genes were identified. PMRGs were abundantly expressed in tumor cells, with 12 survival-related genes being selected. In the METABRIC cohort, two PMRG expression subtypes were identified, with cancer- and immune-related pathways being more active in cluster B, which was associated with a worse prognosis. Six genes were used to construct a prognostic model through univariate and multivariate Cox regression analyses. The predictive performance of the polyamine metabolism model was validated by ROC curve analysis (training cohort: METABRIC, AUC3years=0.684; validation cohort: GSE86166, AUC3years=0.682). A nomogram combining risk scores and clinicopathological features was constructed. Decision Curve Analysis (DCA) demonstrated that the model could guide clinical treatment strategies. Four high-risk independent prognostic factors ( Conclusions: This study elucidated the biological characteristics of PMRG expression subtypes in BC, identifying a polyamine-related prognostic signature and four novel biomarkers to accurately predict prognosis and immunotherapy response in BC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.